Old Web
English
Sign In
Acemap
>
authorDetail
>
Makoto Kamiya
Makoto Kamiya
Taisho Pharmaceutical Co.
Endocrinology
Placebo-controlled study
Internal medicine
Clinical endpoint
Major depressive disorder
2
Papers
6
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data.
2021
Biopharmaceutics & Drug Disposition
Shoko Inatani
Akiko Mizuno-Yasuhira
Makoto Kamiya
Izumi Nishino
Helene D. Sabia
Hiromi Endo
Show All
Source
Cite
Save
Citations (1)
Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study
2020
Journal of Psychiatric Research
Makoto Kamiya
Helene D. Sabia
Julie Marella
Maurizio Fava
Charles B. Nemeroff
Hideo Umeuchi
Michihiko Iijima
Shigeyuki Chaki
Izumi Nishino
Show All
Source
Cite
Save
Citations (5)
1